Mikael S. Lindstrm

List of Publications by Year in Descending Order

46 papers	2,553 citations	27 h-index	50 g-index
51 ext. papers	2,923 ext. citations	7.2 avg, IF	5.38 L-index

#	Paper	IF	Citations
46	SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma. *Oncogene*, **2021**, 40, 5066-5080	9.2	2
45	The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. *Science Advances*, **2021**, 7,	14.3	6
44	Identification of functionally distinct and interacting cancer cell subpopulations from glioblastoma with intratumoral genetic heterogeneity. *Neuro-Oncology Advances*, **2020**, 2, vdaa061	0.9	5
43	Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds. *Cancer Research*, **2020**, 80, 1538-1550	10.1	9
42	The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity. *Cell Death and Differentiation*, **2020**, 27, 773-789	12.7	17
41	Expanding the scope of candidate prognostic marker IGFBP2 in glioblastoma. *Bioscience Reports*, **2019**, 39,	4.1	3
40	Nucleolus as an emerging hub in maintenance of genome stability and cancer pathogenesis. *Oncogene*, **2018**, 37, 2351-2366	9.2	101
39	Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype. *Cancer Research*, **2018**, 78, 5901-5916	10.1	9
38	DNA damage-induced dynamic changes in abundance and cytosol-nuclear translocation of proteins involved in translational processes, metabolism, and autophagy. *Cell Cycle*, **2018**, 17, 2146-2163	4.7	4
37	Human cytomegalovirus and Herpes Simplex type I virus can engage RNA polymerase I for transcription of immediate early genes. *Oncotarget*, **2017**, 8, 96536-96552	3.3	4
36	Role of ribosomal protein mutations in tumor development (Review). *International Journal of Oncology*, **2016**, 48, 1313-24	4.4	93
35	NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape. *Scientific Reports*, **2015**, 5, 16495	4.9	31
34	Disruption of the 5S RNP-Mdm2 interaction significantly improves the erythroid defect in a mouse model for Diamond-Blackfan anemia. *Leukemia*, **2015**, 29, 2221-9	10.7	27
33	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. *Genes and Development*, **2014**, 28, 58-70	12.6	121
32	Loss of nucleolar histone chaperone NPM1 triggers rearrangement of heterochromatin and synergizes with a deficiency in DNA methyltransferase DNMT3A to drive ribosomal DNA transcription. *Journal of Biological Chemistry*, **2014**, 289, 34601-19	5.4	34
31	mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels. *Cancer Biology and Therapy*, **2014**, 15, 1499-514	4.6	23
30	The Nucleolus as a Stress Response Organelle **2013**, 251-273		7

29	Transcription factor PROX1: its role in development and cancer. *Cancer and Metastasis Reviews*, **2012**, 31, 793-805	9.6	89
28	Elucidation of motifs in ribosomal protein S9 that mediate its nucleolar localization and binding to NPM1/nucleophosmin. *PLoS ONE*, **2012**, 7, e52476	3.7	20
27	p53 -Dependent and -Independent Nucleolar Stress Responses. *Cells*, **2012**, 1, 774-98	7.9	64
26	PDGF and PDGF receptors in glioma. *Upsala Journal of Medical Sciences*, **2012**, 117, 99-112	2.8	120
25	Uncoupling of the ER□regulated morphological phenotype from the cancer stem cell phenotype in human breast cancer cell lines. *Biochemical and Biophysical Research Communications*, **2011**, 405, 581-7	3.4	7
24	Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. *Journal of Oncology*, **2011**, 2011, 852970	4.5	21
23	Brain abnormalities and glioma-like lesions in mice overexpressing the long isoform of PDGF-A in astrocytic cells. *PLoS ONE*, **2011**, 6, e18303	3.7	20
22	PROX1 is a predictor of survival for gliomas WHO grade II. *British Journal of Cancer*, **2011**, 104, 1747-54	8.7	32
21	NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling. *Biochemistry Research International*, **2011**, 2011, 195209	2.4	204
20	Silencing of ribosomal protein S9 elicits a multitude of cellular responses inhibiting the growth of cancer cells subsequent to p53 activation. *PLoS ONE*, **2010**, 5, e9578	3.7	61
19	An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. *Cancer Cell*, **2010**, 18, 231-43	24.3	161
18	Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas. *Journal of Neuropathology and Experimental Neurology*, **2010**, 69, 129-38	3.1	40
17	Emerging functions of ribosomal proteins in gene-specific transcription and translation. *Biochemical and Biophysical Research Communications*, **2009**, 379, 167-70	3.4	127
16	Ribosomal protein S9 is a novel B23/NPM-binding protein required for normal cell proliferation. *Journal of Biological Chemistry*, **2008**, 283, 15568-76	5.4	96
15	Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. *Cancer Cell*, **2007**, 12, 355-66	24.3	209
14	Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions. *Cell Cycle*, **2007**, 6, 434-7	4.7	52
13	Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. *Molecular and Cellular Biology*, **2007**, 27, 1056-68	4.8	115
12	p16INK4a and laminin-5gamma2 chain expression during the progression of cervical neoplasia. *Acta Oncol□gica*, **2006**, 45, 676-84	3.2	2

11	Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. *Journal of Biological Chemistry*, **2006**, 281, 18463-72	5.4	50
10	B23 and ARF: friends or foes?. *Cell Biochemistry and Biophysics*, **2006**, 46, 79-90	3.2	38
9	p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia. *Modern Pathology*, **2005**, 18, 629-37	9.8	40
8	Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. *Clinical Cancer Research*, **2004**, 10, 2407-14	12.9	86
7	Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts. *Oncogene*, **2003**, 22, 4993-5005	9.2	65
6	Role of genetic and epigenetic changes in Burkitt lymphoma. *Seminars in Cancer Biology*, **2002**, 12, 381-7	12.7	90
5	A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. *Cancer Letters*, **2002**, 180, 211-21	9.9	15
4	Inactivation of Myc-induced p53-dependent apoptosis in human tumors. *Apoptosis: an International Journal on Programmed Cell Death*, **2001**, 6, 133-7	5.4	25
3	p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. *Oncogene*, **2001**, 20, 2171-7	9.2	84
2	MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. *Journal of Biological Chemistry*, **2001**, 276, 25336-41	5.4	44
1	Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. *Experimental Cell Research*, **2000**, 256, 400-10	4.2	77